Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa

Vaccine

Volumn 32, Issue 17, 2014, Pages 1954-1963

  Kim, Sun Young ^a   Russell, Louise B ^b   Park, Jeehyun ^b   Verani, Jennifer R ^c   Madhi, Shabir A ^d   Cutland, Clare L ^d   Schrag, Stephanie J ^c   Sinha, Anushua ^e  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^d NATIONAL RESEARCH FOUNDATION   (South Africa)

^e RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Cost effectiveness; GBS vaccine; Group B streptococcal (GBS); Intrapartum antibiotic prophylaxis (IAP); Neonatal sepsis; South Africa

Indexed keywords

STREPTOCOCCUS VACCINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DRUG COST; GROUP B STREPTOCOCCAL INFECTION; HUMAN; INFANT MORTALITY; INFECTION PREVENTION; NEWBORN INFECTION; PREGNANT WOMAN; PRIORITY JOURNAL; SEROTYPE; SIMULATION; SOUTH AFRICA; VACCINATION;

COST-EFFECTIVENESS; GBS VACCINE; GROUP B STREPTOCOCCAL (GBS); INTRAPARTUM ANTIBIOTIC PROPHYLAXIS (IAP); NEONATAL SEPSIS; SOUTH AFRICA;

ANTIBIOTIC PROPHYLAXIS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MODELS, ECONOMIC; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS; SOUTH AFRICA; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS AGALACTIAE; VACCINATION;

EID: 84896319151     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.062     Document Type: Article

References (43)

1. Le Doare K., Heath P.T. An overview of global GBS epidemiology. Vaccine 2013, 31(Supplement 4):D7-D12.
2. Edmond K.M., Kortsalioudaki C., Scott S., Schrag S.J., Zaidi A.K., Cousens S., et al. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 2012, 379:547-556.
3. Madhi S.A., Radebe K., Crewe-Brown H., Frasch C.E., Arakere G., Mokhachane M., et al. High burden of invasive Streptococcus agalactiae disease in South African infants. Ann Trop Paediatr 2003, 23:15-23.
4. Bomela H.N., Ballot D.E., Cooper P.A. Is prophylaxis of early-onset group B streptococcal disease appropriate for South Africa. S Afr Med J 2001, 91:858-860.
5. Cutland C.L., Madhi S.A., Zell E.R., Kuwanda L., Laque M., Groome M., et al. Chlorhexidine maternal-vaginal and neonate body wipes in sepsis and vertical transmission of pathogenic bacteria in South Africa: a randomised, controlled trial. Lancet 2009, 374:1909-1916.
6. Cutland C.L., Schrag S.J., Zell E.R., Kuwanda L., Buchmann E., Velaphi S.C., et al. Maternal HIV infection and vertical transmission of pathogenic bacteria. Pediatrics 2012, 130:e581-e590.
7. Lin F.Y., Philips J.B., Azimi P.H., Weisman L.E., Clark P., Rhoads G.G., et al. Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study. J Infect Dis 2001, 184:1022-1028.
8. Lin F.Y., Weisman L.E., Azimi P.H., Philips J.B., Clark P., Regan J., et al. Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. J Infect Dis 2004, 190:928-934.
9. Baker C.J., Edwards M.S. Group B streptococcal conjugate vaccines. Arch Dis Child 2003, 88:375-378.
10. Chen V.L., Avci F.Y., Kasper D.L. A maternal vaccine against group B Streptococcus: past, present, and future. Vaccine 2013, 31(Supplement 4):D13-D19.
11. Heath P.T. An update on vaccination against group B streptococcus. Expert Rev Vaccines 2011, 10:685-694.
12. National Library of Medicine (US). ClinicalTrials.gov. http://www.clinicaltrials.gov www.clinicaltrials.gov (accessed June 7, 2013).
13. CDC Prevention of perinatal group B streptococcal disease: revised guidelines from CDC, 2010. Morb Mortal Wkly Rep 2010, 59:1-32.
14. Schrag S.J., Verani J.R. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine. Vaccine 2013, 31(Supplement 4):D20-D26.
15. Schrag S.J., Cutland C.L., Zell E.R., Kuwanda L., Buchmann E.J., Velaphi S.C., et al. Risk factors for neonatal sepsis and perinatal death among infants enrolled in the prevention of perinatal sepsis trial, Soweto, South Africa. Pediatr Infect Dis J 2012, 31:821-826.
16. Schrag S.J. Group B streptococcal vaccine for resource-poor countries. Lancet 2011, 378:11-12.
17. Recorded live births, 2010 2011, Statistics South Africa.
18. District Health Information System Health Systems Trust 2010.
19. Ataguba J.E., McIntyre D. Paying for and receiving benefits from health services in South Africa: is the health system equitable?. Health Policy Plann 2012, 27:i35-i45.
20. UNICEF Immunization summary: a statistical reference containing data through 2009 2011, The United Nations Children's Fund (UNICEF), New York. The 2011 ed.
21. Madzivhandila M., Adrian P.V., Cutland C.L., Kuwanda L., Schrag S.J., Madhi S.A. Serotype distribution and invasive potential of group B streptococcus isolates causing disease in infants and colonizing maternal-newborn dyads. PLoS ONE 2011, 6:e17861.
22. Lin F.Y., Brenner R.A., Johnson Y.R., Azimi P.H., Philips J.B., Regan J.A., et al. The effectiveness of risk-based intrapartum chemoprophylaxis for the prevention of early-onset neonatal group B streptococcal disease. Am J Obstet Gynecol 2001, 184:1204-1210.
23. Fairlie T., Zell E.R., Schrag S.J. Effectiveness of intrapartum antibiotic prophylaxis for prevention of early-onset group B streptococcal disease. Obstet Gynecol 2013, 121:1-9.
24. Kellogg J.A., Ferrentino F.L., Goodstein M.H., Liss J., Shapiro S.L., Bankert D.A. Frequency of low level bacteremia in infants from birth to two months of age. Pediatr Infect Dis J 1997, 16:381-385.
25. World development indicators 2012 2012, The World Bank, Washington.
26. Gold M., Siegel J.E., Russell L.B., Weinstein M.C. Cost-effectiveness in Health and Medicine 1996, Oxford University Press, New York City.
27. WHO The World Health Report 2002: reducing risks, promoting healthy life 2002, World Health Organization, Geneva
28. Schuchat A. Group B streptococcus. Lancet 1999, 353:51-56.
29. Bryce J., Boschi-Pinto C., Shibuya K., Black R.E. WHO estimates of the causes of death in children. Lancet 2005, 365:1147-1152.
30. Lozano R., Wang H., Foreman K.J., Rajaratnam J.K., Naghavi M., Marcus J.R., et al. Progress towards Millennium Development Goals 4 and 5 on maternal and child mortality: an updated systematic analysis. Lancet 2011, 378:1139-1165.
31. Mohle-Boetani J.C., Schuchat A., Plikaytis B.D., Smith J.D., Broome C.V. Comparison of prevention strategies for neonatal group B streptococcal infection. A population-based economic analysis. JAMA 1993, 270:1442-1448.
32. Vaccines for the 21st century: a tool for decision making: Institute of Medicine 2000, K.R.D. Stratton, S. Jane, Lawrence, S. Robert (Eds.).
33. Sinha A., Lieu T.A., Paoletti L.C., Weinstein M.C., Platt R. The projected health benefits of maternal group B streptococcal vaccination in the era of chemoprophylaxis. Vaccine 2005, 23:3187-3195.
34. Colbourn T., Asseburg C., Bojke L., Philips Z., Claxton K., Ades A.E., et al. Prenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses. Health Technol Assess 2007, 11:1-226. iii.
35. Kwatra G., Madhi S.A., Cutland C.L., Buchmann E.J., Adrian P.V. Comparison of CHROMagar StrepB, Columbia CNA agar and Lim broth for the isolation of Group B Streptococcus from vaginal and rectal swabs from South Africa 2013, Johannesburg.
36. Goldenberg R.L., Culhane J.F., Iams J.D., Romero R. Epidemiology and causes of preterm birth. Lancet 2008, 371:75-84.
37. South Africa Demographic and Health Survey 2003 Department of Health, Medical Research Council 2007, OrcMacro.
38. Beck S., Wojdyla D., Say L., Betran A.P., Merialdi M., Requejo J.H., et al. The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bull World Health Organ 2010, 88:31-38.
39. Griffiths U.K. The costs of waste management of sharps from immunization activities: a case study from South Africa 2001, WHO, Geneva, [First Draft].
40. Sinha A., Kim S., Ginsberg G., Franklin H., Kohberger R., Strutton D., et al. Economic burden of acute lower respiratory tract infection in South African children. Paediatr Int Child Health 2012, 32:65-73.
41. MacIntyre U.E., de Villiers F.P. The economic burden of diarrheal disease in a tertiary level hospital, Gauteng, South Africa. J Infect Dis 2010, 202(Suppl.):S116-S125.
42. Monthly earnings of South Africans, 2010 2010, Statistics South Africa, Pretoria.
43. Salomon J.A., Vos T., Hogan D.R., Gagnon M., Naghavi M., Mokdad A., et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012, 380:2129-2143.